CA
ACTU

Cliff Asness’s Actuate Therapeutics ACTU Stock Holding History

Cliff Asness’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Buy
127,493
+100,384
+370% +$233K ﹤0.01% 3805
2026
Q1 		$74.3K Buy
+27,109
New +$112K ﹤0.01% 3699

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

Cliff Asness's ACTU Position: Q2 2026 in Review

Cliff Asness increased its Actuate Therapeutics (ACTU) stake by 370% in Q2 2026, buying an estimated $233K and bringing the position to 127,493 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3805.

Cliff Asness first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Cliff Asness held 127,493 shares of Actuate Therapeutics worth $195K as of Q2 2026.
  • Cliff Asness bought 100,384 Actuate Therapeutics shares in Q2 2026, an estimated $233K.
  • Actuate Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3805 holding.
  • Cliff Asness first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.